Advertisement
Advertisement
REGN
Regeneron Pharmaceuticals Inc
768.58
USDSponsored
+7.92
+1.04%
Aug 05, 15:59 UTC -4
Closed
After-Market
767.34
-1.24
-0.16%
REGN Earnings Reports
Positive Surprise Ratio
REGN beat 35 of 42 last estimates.
83%
Next Report
Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$4.34B
/$13.69
Implied change from Q2 26 (Revenue/ EPS)
+1.17%
/-4.20%
Implied change from Q3 25 (Revenue/ EPS)
+15.63%
/+15.72%
Regeneron Pharmaceuticals Inc earnings per share and revenue
On Jul 30, 2026, REGN reported earnings of 14.29 USD per share (EPS) for Q2 26, beating the estimate of 10.46 USD, resulting in a 36.51% surprise. Revenue reached 4.29 billion, compared to an expected 3.89 billion, with a 10.22% difference. The market reacted with a +6.17% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of 13.69 USD, with revenue projected to reach 4.34 billion USD, implying an decrease of -4.20% EPS, and increase of 1.17% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Royalty Pharma plc Class A Ordinary Shares
Report Date
Aug 05, 2026 For Q2 26
Estimate
$1.30
Actual
$1.32
Surprise
+1.30%
Revolution Medicines, Inc. Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$2.01
Actual
-$2.34
Surprise
-16.00%
Exelixis Inc
Report Date
Aug 05, 2026 For Q2 26
Estimate
$0.80
Actual
$0.91
Surprise
+13.51%
Mirum Pharmaceuticals, Inc. Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.80
Surprise
-15.21%
GRAIL, Inc. Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$2.70
Actual
-$2.56
Surprise
+5.37%
Recursion Pharmaceuticals, Inc. Class A Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.25
Surprise
-4.73%
Vir Biotechnology, Inc. Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
$0.33
Actual
$0.47
Surprise
+39.76%
Emergent Biosolutions, Inc.
Report Date
Aug 05, 2026 For Q2 26
Estimate
$0.11
Actual
$0.60
Surprise
+440.05%
Vanda Pharmaceuticals Inc.
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.59
Actual
-$1.04
Surprise
-73.54%
Editas Medicine, Inc. Common Stock
Report Date
Aug 05, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.15
Surprise
+45.16%
FAQ
What were Regeneron Pharmaceuticals Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Regeneron Pharmaceuticals Inc reported EPS of $14.29, beating estimates by 36.51%, and revenue of $4.29B, 10.22% above expectations.
How did the market react to Regeneron Pharmaceuticals Inc's Q2 2026 earnings?
The stock price moved up 6.17%, changed from $695.42 before the earnings release to $738.34 the day after.
When is Regeneron Pharmaceuticals Inc expected to report next?
The next earning report is scheduled for Oct 26, 2026.
What are the forecasts for Regeneron Pharmaceuticals Inc's next earnings report?
Based on 10
analysts, Regeneron Pharmaceuticals Inc is expected to report EPS of $13.69 and revenue of $4.34B for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement